Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aims: New drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due regulatory requirements from the Food and Drug Administration. For this reason, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) are currently undergoing large‐scale, long‐term randomized trials specifically designed for cardiovascular outcomes. Aim of the present meta‐analysis of randomized clinical trials is the assessment of the effects of GLP‐1 RA on major cardiovascular events (MACE), mortality and cardiovascular risk factors. Methods: A meta‐analysis was performed including all trials with a duration of at least 6 months, comparing a GLP‐1 RA with a non‐GLP‐1 RA agent in type 2 diabetes. MACE and mortality were retrieved and combined to calculate Mantel–Haenzel odds ratio ( MH‐OR ). Furthermore, data on endpoint systolic and diastolic blood pressure, total and high‐density lipoprotein (HDL) cholesterol and triglyceride were collected. Results: Of 37 selected trials, 33 reported information on MACE , and 25 reported at least one event. The difference in the incidence of MACE between GLP‐1 RA and comparators did not reach statistical significance [ MH‐OR 0.78 (0.54–1.13), p = 0.18]. GLP‐1 RA were associated with a significant reduction in the incidence of MACE in comparisons with placebo and pioglitazone, with a non‐significant trend towards reduction in DPP4i ‐controlled studies. No significant effect of GLP‐1 RA was observed on mortality, although a non‐significant favourable trend was observed in comparisons with placebo. Conclusions: The present meta‐analysis confirms the cardiovascular safety of GLP‐1 RA, at least in the short term and in low‐risk individuals. GLP‐1 RA could have a beneficial effect on the incidence of MACE , at least in comparison with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803
Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Pinelli, N. R., & Hurren, K. M. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q024 · Cited by 59
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
Research works printed but not linked: 16
- 10.1530/EJE-09-0101 · DOI
- 10.1155/2012/672658 · DOI · Paper page
- Chiquette E, 2012, Chilton R Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers, Vasc Health Risk Manag, 8, 621
- 10.1016/j.numecd.2008.08.002 · DOI
- 10.1111/j.1463-1326.2010.01345.x · DOI
- 10.1038/sj.bjp.0706780 · DOI · Paper page
- 10.7326/0003-4819-151-4-200908180-00135 · DOI · Paper page
- 10.1016/0197-2456(95)00134-4 · DOI · Paper page
- 10.2307/2533446 · DOI · Paper page
- 10.1136/bmj.315.7109.629 · DOI · Paper page
- 10.1155/2011/215764 · DOI
- 10.1177/1479164111408937 · DOI · Paper page
- 10.1016/j.numecd.2009.03.021 · DOI · Paper page
- 10.1056/NEJM198104023041401 · DOI · Paper page
- The MACB Study Group, 1995, Effect of metoprolol on death and cardiac events during a 2‐year period after coronary artery bypass grafting, Eur Heart J, 16, 1825, 10.1093/oxfordjournals.eurheartj.a060835 · DOI
- 10.1111/dom.12000 · DOI · Paper page
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“…hemodynamic equilibrium, 18 diminish thrombotic propensity, 448 alleviate endothelial oxidative stress, 449 attenuate in fl ammatory processes, 450 and foster a favorable balance of the gut microbiota, 451 all of which collectively contribute to the salutary effects of these agents in…”
BackgroundGlucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
“As noted above, meta-analysis findings suggest no increased risk of major adverse cardiovascular events in patients receiving GLP-1 receptor agonists, and there is some suggestion of potential benefit (29).”
ResultA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304
“The beneficial BP lowering effect associated with exenatide and liraglutide observed in our analysis was consistent with previous meta-analyses, with reduction of 1 to 5 mmHg compared with placebo and active comparators [14–17].”
BackgroundResultInfluentialSun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232
“A major strength of our study was the inclusion of a substantially greater number of trials with dosages of GLP-1 RAs distinct from earlier meta-analyses.(13,14) It is the largest completed evaluation of GLP-1 RAs on lipid profiles to date.”
ResultGLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Self-citationEffects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97
Lundkvist, P., Pereira, M. J., Katsogiannos, P., Sjöström, C. D., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12954 · Cited by 72
Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries
Niafar, M., Pourafkari, L., Porhomayon, J., & Nader, N. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3976-7 · Cited by 66
Janssen, L. G. M., Nahon, K. J., Bracké, K. F. M., van den Broek, D., Smit, R., Sardjoe Mishre, A. S. D., Koorneef, L. L., Martinez-Tellez, B., Burakiewicz, J., Kan, H. E., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154167 · Cited by 54
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Kang, Y. M., & Jung, C. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.258 · Cited by 51
Yang, Y.-S., Chen, H.-H., Huang, C.-N., Hsu, C. Y., Hu, K.-C., & Kao, C.-H. (2022) · Diabetes Care · doi:10.2337/dc21-1993 · Cited by 35
Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
Premji, R., Nylen, E. S., Naser, N., Gandhi, S., Burman, K. D., & Sen, S. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0004 · Cited by 18
“It appears that this is not isolated to one type of GLP-1a since a meta-analysis suggests a class effect 29,30 as LDL was modestly, but significantly reduced for all GLP-1a used versus placebo (range - 0.08 to - 0.16 mM), including weekly administered GLP-1a.”
InfluentialScheen, A. J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.009 · Cited by 18
Bhattarai, H. B., Paudel, B. S., Parajuli, S. R., Dahal, K., Shah, S., Bhattarai, M., Baral, B., Karki, B., Basnet, B., Bhandari, A., et al. (2025) · Medicine · doi:10.1097/md.0000000000046671 · Cited by 5
“[6] Understanding the prevalence and nature of GI side effects associated with non-peptide GLP-1 RA is essential for optimizing their clinical use and devising appropriate patient management strategies.”
Metadata
- Authors
- Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-07-28
- Volume
- 16
- Issue
- 1
- Pages
- 38-47
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1966379378
- Cited by
- 174
- References
- 9
- FWCI
- 22.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.